Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer.
10.19540/j.cnki.cjcmm.20221201.704
- Author:
Fang LI
1
;
Rui-Yang YAN
1
;
Kai-Yang LI
1
;
Jue WANG
1
;
Li WANG
1
;
Hui SHEN
1
;
Cai-Li HAN
1
;
Min LIU
2
Author Information
1. Medical College, Yan'an University Yan'an 716000, China.
2. Oncology Department, Affiliated Hospital of Yan'an University Yan'an 716000, China.
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
combination therapy;
irinotecan;
molecular mechanism;
resveratrol
- MeSH:
Humans;
Irinotecan;
Colorectal Neoplasms/genetics*;
Resveratrol;
Molecular Docking Simulation;
ErbB Receptors/genetics*
- From:
China Journal of Chinese Materia Medica
2023;48(8):2212-2221
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to investigate the mechanism of resveratrol(RES) combined with irinotecan(IRI) in the treatment of colorectal cancer(CRC). The targets of RES, IRI, and CRC were obtained from databases, and the targets of RES combined with IRI in the treatment of CRC were acquired by Venn diagram. The protein functional cluster analysis, GO and KEGG enrichment analyses were performed. In addition, the protein-protein interaction(PPI) network was constructed. The core target genes were screened out and the target-signaling pathway network was set up. IGEMDOCK was used to dock the core target gene molecules. Besides, the relationship between the expression level of key target genes and the prognosis and immune infiltration of CRC was analyzed. Based on the in vitro cell experiment, the molecular mechanism of RES combined with IRI in the treatment of CRC was explored and analyzed. According to the results, 63 potential targets of RES combined with IRI were obtained for CRC treatment. Furthermore, cluster analysis revealed that protein functions included 23% transmembrane signal receptors, 22% protein modifying enzymes, and 14% metabolite converting enzymes. GO analysis indicated that BPs were mainly concentrated in protein autophosphorylation, CCs in receptor complex and plasma membrane, and MFs in transmembrane receptor protein tyrosine kinase activity. Moreover, KEGG signaling pathways were mainly enriched in central carbon metabolism in cancer. The key targets of RES combined with IRI in the treatment of CRC were PIK3CA, EGFR, and IGF1R, all of which were significantly positively correlated with the immune infiltration of CRC. As shown by the molecular docking results, PIK3CA had the most stable binding with RES and IRI. Compared with the results in the control group, the proliferation ability and EGFR protein expression of CRC cells in the RES-treated group, the IRI-treated group, and the RES+IRI treated group significantly decreased. Moreover, the cell proliferation ability and EGFR protein expression level of CRC cells in the RES+IRI treated group were remarkably lower than those in the IRI-treated group. In conclusion, PIK3CA, EGFR, and IGF1R are the key targets of RES combined with IRI in CRC treatment. In addition, RES can inhibit the proliferation of CRC cells and improve IRI chemoresistance by downregulating the EGFR signaling pathway.
